FDA approves ARISTADATM for treatment of schizophrenia
Alkermes announced the FDA has approved ARISTADA™ (aripiprazole lauroxil) ER injectable suspension for treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication. October 05, 2015